• CEO interview: Growth Strategy of Shionogi

What's New

  • Show All
2018/04/19
SHIONOGI TO PRESENT NEW DATA AT 2018 EUROPEAN CONGRESS OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES
2018/04/17
SHIONOGI ENTERS INTO LICENSE AGREEMENT WITH PHARMBIO KOREA FOR OSPEMIFENE
2018/03/26
Research Collaboration between Kyoto University and Shionogi at Kyoto University’s open innovation laboratory -Drug discovery and medical research for the treatment of psychiatric disorders-
2018/03/23
Audio Webcasting of the R&D Meeting
2018/03/22
Shionogi Announces Agreement with CARB-X for an Innovative AMR (Anti Microbial Resistance) Program
2018/03/19
Shionogi to Announce Executive Appointments
2018/03/15
R&D Meeting
2018/03/14
XOFLUZA (Baloxavir Marboxil) Tablets 10mg/20mg for the Treatment of Influenza Types A and B launched in Japan
2018/03/12
Notice Regarding Completion of Cancellation of Treasury Shares(Cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act)
2018/02/28
Shionogi to Announce Corporate Reorganization and Personnel Reassignment
2018/02/27
Shionogi Announces FDA New Drug Application (NDA) and EMA Marketing Authorization Application (MAA) Acceptances for Lusutrombopag (S-888711) -In the United States, Lusutrombopag Granted Priority Review by the FDA-
2018/02/23
XOFLUZA (Baloxavir Marboxil) Tablets 10mg/20mg Approved for the Treatment of Influenza Types A and B in Japan
2018/02/16
Notice of Completion of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)